PD1抑制剂联合白蛋白结合型紫杉醇和顺铂化疗方案二线治疗晚期胃癌患者的临床研究  

Clinical Study of PD1 Inhibitor Combined with Albumin-bound Paclitaxel and Cisplatin Chemotherapy Regimen for Second-line Treatment of Pa⁃tients with Advanced Gastric Cancer

作　　者：王燕 王晓丽 曹永峰[1] 施向荣[1] WANG Yan;WANG Xiaoli;CAO Yongfeng;SHI Xiangrong(Department of Medical Oncology,Nantong Tumor Hospital,Nantong 226000,Jiangsu,China)

机构地区：[1]南通市肿瘤医院肿瘤内科,江苏南通226000

出　　处：《系统医学》2025年第7期87-90,共4页Systems Medicine

摘　　要：目的 探讨晚期胃癌患者应用程序性死亡受体1(programmed cell death protein 1, PD1)抑制剂联合白蛋白结合型紫杉醇和顺铂化疗方案的治疗效果。方法 随机选取2021年1月—2023年9月南通市肿瘤医院肿瘤内科收治的70例一线化疗失败的晚期胃癌患者为研究对象,按照治疗方案将患者分为对照组(n=35,仅接受化疗方案)和观察组(n=35,接受化疗方案和PD1抑制剂治疗)。比较两组治疗效果、肿瘤标志物水平、生活质量评分和不良事件发生情况。结果 观察组疾病控制率为85.71%(30/35),高于对照组的62.86%(22/35),差异有统计学意义(χ^(2)=4.786,P<0.05)。观察组肿瘤标志物水平优于对照组,差异均有统计学意义(P均<0.05)。两组生活质量评分、不良反应发生率比较,差异均无统计学意义(P均>0.05)。结论 应用PD1抑制剂联合白蛋白结合型紫杉醇和顺铂化疗方案治疗晚期胃癌患者的效果较好,安全性较高。Objective To investigate the therapeutic efficacy of a programmed cell death protein 1(PD1)inhibitor combined with albumin-bound paclitaxel and cisplatin chemotherapy regimen in patients with advanced gastric can⁃cer.Methods Seventy patients with advanced gastric cancer who failed first-line chemotherapy admitted to the De⁃partment of Medical Oncology of Nantong Cancer Hospital from January 2021 to September 2023 were randomly se⁃lected as study subjects,and the patients were divided into the control group(n=35,receiving only chemotherapy regi⁃men)and the observation group(n=35,receiving chemotherapy regimen and PD1 inhibitor treatment)according to the treatment plan.The treatment effects,tumor marker levels,quality of life scores and occurrence of adverse events were compared between the two groups.Results The disease control rate of the observation group was 85.71%(30/35),which was higher than 62.86%(22/35)in the control group,and the difference was statistically significant(χ^(2)=4.786,P<0.05).The level of tumor markers in the observation group was better than those in the control group,and the differ⁃ences were statistically significant(all P<0.05).There were no statistically significant differences in the quality of life scores and incidence of adverse reactions between the two groups(all P>0.05).Conclusion The application of PD1 in⁃hibitors combined with albumin-bound paclitaxel and cisplatin chemotherapy regimens for the treatment of patients with advanced gastric cancer is effective and high safety.

关 键 词：胃癌 程序性死亡受体1 化疗 疾病控制率 肿瘤标志物 生活质量 

分 类 号：R735[医药卫生—肿瘤]